Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 9/20 | 0.65 |
| ▸ | NPC1 | O15118 | 7/20 | 0.65 |
| ▸ | CASP6 | P55212 | 1/20 | 0.63 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL719495 | 0.85 | NPC1 (0.50) | RAB9ANPC1CASP6ALDH1A1HPGD | |
| SCHEMBL717829 | 0.84 | NPC1 (0.68) | RAB9ANPC1CASP6ALDH1A1LMNA | |
| SCHEMBL716884 | 0.83 | NPC1 (0.66) | RAB9ANPC1CASP6ALDH1A1LMNA | |
| SCHEMBL717973 | 0.80 | ALDH1A1 (0.46) | RAB9ANPC1CASP6ALDH1A1LMNA | |
| SCHEMBL3617512 | 0.77 | MCL1 (0.67) | RAB9ANPC1CASP6KCNH2ALDH1A1 | |
| SCHEMBL24756245 | 0.77 | RAB9A (0.62) | RAB9ANPC1ALDH1A1LMNAHPGD | |
| SCHEMBL719882 | 0.77 | NPC1 (0.46) | RAB9ANPC1CASP6ALDH1A1HPGD | |
| SCHEMBL717995 | 0.77 | RAB9A (0.56) | RAB9ANPC1ALDH1A1LMNAHPGD | |
| SCHEMBL716722 | 0.77 | RAB9A (0.51) | RAB9ANPC1ALDH1A1HPGDTSHR | |
| SCHEMBL13787073 | 0.76 | CASP6 (0.62) | RAB9ANPC1CASP6KCNH2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8436043-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-07 | — | — | US | disclosed |
| US-20120270865-A2 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-25 | — | — | US | disclosed |
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-01 | — | — | US | disclosed |
| EP-2251326-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | RAB9A 2454/4885NPC1 902/4885CASP6 831/4885 |
| US-20120270865-A2 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | RAB9A 2454/4885NPC1 902/4885CASP6 831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.